ANGLE is a specialist medtech company listed on the London Stock Exchange AIM market (AGL.L).
ANGLE's lead product is the Parsortix micro-fluidic cell separation device, which can capture very rare circulating tumour cells (CTCs) in cancer patient blood – even when there is less than one CTC in one billion healthy cells. ANGLE secured CE Mark regulatory authorisation for the clinical market in December 2013 and FDA authorisation work is in progress.
The primary application is the capture of circulating tumour cells (CTCs) in patient blood for:
· Early detection of cancer;
· Personalised cancer treatment;
· Monitoring of cancer patients during treatment; and
· Post-treatment monitoring of cancer patients in remission.
Mandalay Resources creates exceptional shareholder value through the acquisition of undervalued assets that can: become rapidly cash generative, self fund exploration, establish and maintain high operating margins, and return cash to shareholders. Mandalay is committed to operating safely and in an environmentally responsible manner, while developing a high level of community and employee engagement.
Royal Road Minerals
Royal Road Minerals is a gold and copper focused exploration and development company. The Company’s objective is to advance the exploration and development of its projects in Colombia and Nicaragua and to discover new assets in Colombia and Nicaragua. The Company’s priority is the discovery and acquisition of high-grade, high-margin copper and gold projects in highly prospective regions and in sustainable and inclusive arrangements with local joint venture partners. Royal Road Minerals has a strong social and environmental conscience and aims to exemplify world’s best practice in regards to all aspects of gold exploration and development.